Grove announce $4.9 million seed round to revolutionize participant relationships in clinical trials. With the support of industry investors, led by A* with participation from Afore Capital, LifeX Ventures, Pear VC, Upfront Ventures, and industry-leading angels including Ajit Baid (former Head of Global Asset at UCB), Chloe Yoo (Director at ICON, former CFO at HumanFirst), Phuc Truong (former Co-Founder of CRIO), and Till Pieper (former Google Cloud AI lead).
Read also – Stellar Raises $2.7 Mn in Oversubscribed Seed Round
Grove has spent hundreds of hours visiting clinical trial sites, shadowing staff, speaking with participants, and signing up for trials ourselves.
Read also – Aviceda Therapeutics Raises $207.5 Mn in Series C Financing Round
As Gautam Gupta, Co-Founder and General Partner at A* said, “As clinical trials become increasingly complex, the industry requires solutions that not only interpret data but also deliver actionable insights and tangible results.”
For participants, Grace provides personalized, multilingual support around the clock, managing everything from prescreening to follow-up reminders. In the last six months, Grace has facilitated over 250,000 participant interactions and scheduled more than 7,800 in-person appointments at sites across diverse participant populations and therapeutic areas.
For site staff, Grace reduces the heavy administrative burden, enabling researchers to focus on high-quality participant care. Grace has saved clinical research sites over 22,600 hours of manual workflows.
For clinical operations leaders, Grace offers full visibility and control over recruitment and trial operations, providing the scalability needed to accelerate trial timelines and operational goals from months to days.
Funding to expand our reach and deepen partnerships with pharmaceutical sponsors, CROs, and SMOs to drive a more accessible and efficient future for clinical research.
“In just two months of partnering with Grove, we transformed how our teams operate and engage with participants,” said Sean Stanton, co-founder of K2 Medical Research. “We prescreened and booked hundreds of participants for our Alzheimer’s and vaccine trials, freed our staff of thousands of hours of repetitive work, and gained insights that boosted our efficiency and scale. We look forward to expanding our partnership with Grove to launch more sites and trials at scale.”
About Grove
Grove’s AI-accelerated PRM enables clinical research organizations to recruit and engage with participants at scale. Grove is a team of AI engineers and researchers enabling clinical research organizations to accelerate clinical trials at scale using data and AI.
